Pernix Therapeutics Holdings (PTX) Posts Q1 Loss of 26c/Share

Pernix Therapeutics Holdings (NASDAQ: PTX) reported Q1 EPS of ($0.26), which may not compare with the analyst estimate of ($0.05). Revenue for the quarter came in at $19.1 million versus the consensus estimate of $23.65 million.

Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, a non-GAAP measure) was a non-GAAP net loss of approximately $2.0 million for the first quarter of 2014 and $1.4 million for the first quarter of 2013.

For earnings history and earnings-related data on Pernix Therapeutics Holdings (PTX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Optimum Communications gets NYSE non-compliance notice over stock price
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c